Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 26;16(5):319.
doi: 10.1186/cc11430.

Erythropoietin in the critically ill: do we ask the right questions?

Oscar McCook, Michael Georgieff, Angelika Scheuerle, Peter Möller, Christoph Thiemermann, Peter Radermacher

Erythropoietin in the critically ill: do we ask the right questions?

Oscar McCook et al. Crit Care. .

Abstract

There is a plethora of experimental data on the potential therapeutic benefits of recombinant human erythropoietin (rhEPO) and its synthetic derivatives in critical care medicine, in particular in ischemia/reperfusion injury. Most of the recent clinical trials have not shown clear benefits, and, in some patients, EPO-aggravated morbidity and mortality was even reported. Treatment with rhEPO has been successfully used in patients with anemia resulting from chronic kidney disease, but even a subset of this patient population does not adequately respond to rhEPO therapy. The following viewpoint uses rhEPO as an example to highlight the possible pitfalls in current practice using young healthy animals for the evaluation of therapies to treat patients of variable age and underlying chronic co-morbidity.

PubMed Disclaimer

References

    1. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;16:3. doi: 10.1186/2110-5820-1-3. - DOI - PMC - PubMed
    1. Patel NS, Collino M, Yaqoob MM. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care. 2011;16:40. doi: 10.1186/2110-5820-1-40. - DOI - PMC - PubMed
    1. Patel NSA, Nandra KK, Thiemermann C. Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Crit Care. 2012;16:229. doi: 10.1186/cc11315. - DOI - PMC - PubMed
    1. Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W, Cavaletti G, Cerami A, Chopp M, Coleman T, Digicaylioglu M, Ehrenreich H, Erbayraktar S, Erbayraktar Z, Gassmann M, Genc S, Gokmen N, Grasso G, Juul S, Lipton SA, Hand CC, Latini R, Lauria G, Leist M, Newton SS, Petit E, Probert L, Sfacteria A, Siren AL, Talan M. et al. Erythropoietin: not just about erythropoiesis. Lancet. 2010;16:210. doi: 10.1016/S0140-6736(09)61924-3. - DOI - PMC - PubMed
    1. Goldsmith D. Extraordinary popular delusions and the madness of crowds: puncturing the epoietin bubble - lessons for the future. Nephrol Dial Transplant. 2011;16:24–28. doi: 10.1093/ndt/gfq577. - DOI - PubMed

MeSH terms